Sytheon has receive further patent protection for its new turnkey product which treats atopic dermatitis, and its looking for an exclusive partner to help bring it to the OTC dermatological market.

 

According to the company, there is currently an unmet need for a sustainable, safe and cost-effective product for those with mild to moderate Atopic Dermatitis (AD) or eczema. Sytheon has a turnkey product, ActSES, with solid science, patent protection and clinical validation by UC-Davis, CA dermatologists – and a new clinical study on children underway.

Topical therapies are a mainstay treatment for AD, particularly for children or those with mild-to-moderate disease who may not qualify for systemic medications. The complexity of chronic AD is increased by the interplay of skin barrier dysfunction and immune dysregulation, resulting in the perpetuation of AD signs and symptoms.

 

ActSES, a unique synergistic combination product of Isosorbide di-(linoleate/oleate) (Hydra Synol IDL) + Isosorbide di-caprylate (Hydra Synol DOI), has been developed by Sytheon to serve this unmet need. The effects of topically applied ActSES are not limited to barrier repair, but synergistically inhibit inflammatory cascades that amplify pruritus and cutaneous eruption.

 

For ActSES, Sytheon has obtained two new US patents 11,753,414 (method) & 11,753,415 (composition), entitled “Composition and Methods for Treating Atopic Dermatitis.” Sytheon has two earlier US Patents (10,597,402 & 11,312,725), which disclose “compositions and methods for restoring epidermal integrity and function and treating dermatological diseases.”

 

Sytheon is actively looking for an exclusive partnership with the right organization to bring this turnkey product to the OTC dermatological market. To inquire, interested candidates should send the company a message here.  

 

Sytenol A Bakuchiol Is Approved for Use in China